

Press Release

Glycotope is ready to enter into negotiations with international investors

Berlin, August 2006. Glycotope GmbH, a specialist for GlycoEngineering, Immunology and Antibody Development located in Berlin, Germany, has entered into negotiations with international Investors to initialize the next phase of development and expansion of the company.

The Company which was founded in 2001 in Berlin, Germany by Dr. Andreas Eckert, CEO of Eckert & Ziegler Strahlen- und Medizintechnik AG and Dr. Steffen Goletz, has grown through specialized contract research and public funding into a profitable, privately held biotech company, employing 20 people.

Glycotope uses proprietary platform-technologies to optimize and humanize glycosylation, therapeutic Antibodies, fully human glycoproteins and a nutraceutical with specific properties, to stimulate the human immune system against tumors. In addition, the company maintains an interesting product pipeline with antibodies and glycoproteins. The aim of the recent negotiations with representatives of international pharma corporations and venture capital funds is to establish and develop Glycotope GmbH with the full scope of expertise in Berlin to become a leading supplier for products & services in the field of glycomics. Today, the worldwide markets for glycoproteins (antibodies, hormones, growth factors and others) is estimated to be worth some €31 billion, steadily increasing.

The most important milestones on the way to this ambitious goal are the special research funding of more than €1 million Euros from the State of Berlin for the „Glykostrukturfabrik“ – a glycomics-dedicated research network, including the Charité as well as a research project to develop a nutraceutical protecting against tumor cells, funded by the Federal Ministry of Education & Research with over €2 Mio.

The specific research goal of the „Glykostrukturfabrik“ is to further develop the already existing technology-platform GlycoExpress. Today this platform is used to produce glycoproteins with improved efficacy. Under the lead of Glycotope this technology-platform shall be optimized to produce antibodies as well. Therapeutic Antibodies with fully human glycosylation are of special interest because of their higher efficacy and significantly lower side effects.

The nutraceutical project was selected in a regional research competition called „Bioprofile Nutrigenomik“ and had received the highest single project funding by the Federal Ministry of Education & Research. The specific research activities build upon the Glycotope know-how in the fields of immunology and antibody engineering. In close cooperation with the „Deutsches Institut für Ernährungsforschung“ (DifE, Potsdam-Rehbrücke, Prof. Dr. Michael Blaut) as well as the Free University of Berlin (FU, Prof. Dr. Werner Reutter), the development team of Dr. Steffen Goletz has discovered, identified, characterized and tested a new human microorganism which stimulates a specific immune response in the human organism which potentially helps to protect against defined tumor cells.

All company research and development activities are being supported today by successfully marketed services in the fields of glycomics, cell line development and recombinant antibody technologies.

The combination of future oriented technologies & products with an economically stable situation of the company today, is rarely found among young biotech companies. It makes Glycotope a special and promising research partner in the field of glycomics and in Germany.

Glycotope GmbH

Robert-Rössle-Strasse 10
13125 Berlin
www.glycotope.com

CEO

Dr. Steffen Goletz

Contact persons:

Dr. Hans Baumeister, Direktor Business Development (GlycoEngineering)
Email: hans.baumeister@glycotope.com
Tel.: 030 – 941 084 207

Hinrich Schliephack, Head of Business Development (Coreotics)
Email: hinrich.schliephack@glycotope.com
Tel.: 030 – 941 084 332

Deutsches Institut für Ernährungsforschung Potsdam-Rehbrücke (DIfE)

The DIfE is a member institute of the „Leibniz-Gemeinschaft“ which incorporates 84 non-university research and service entities. Leibniz-Institutes work on an interdisciplinary basis, combining basic research with market orientated application development. They are being funded by the German state and federal budgets. More information is available under www.dife.de or www.leibniz-gemeinschaft.de.

BioProfil Nutrigenomik

The competition of „BioProfile“, which was initialized in 2001 and funded by the Federal Ministry of Education & Research (BMBF) was won by the Potsdam / Berlin region. The Federal Government provided €18 Mio in total for project support for various nutrigenomic projects in the State of Berlin and the State of Brandenburg.

The aim of this grant program was to further develop specific existing strengths of selected regions, to explore and exploit new application areas and to sharpen the profile of the region. Academic insights and research results are to be carried over into marketable applications, services and products.

The focal point of the projects being funded in Berlin-Brandenburg have health-oriented character and derive from prevention, diagnostics, therapy and analytics. The main interest concentrates on cardio vascular diseases, diabetics, cancer and allergies.

The funded projects cover research and development over the complete value chain – from identification of possible Drug Targets, up to the development of diagnostics, analytic test kits and pharmaceuticals. Further information: www.nutrigenomik.de

Glykostrukturfabrik

The Glykostrukturfabrik is a research and application oriented network of specialists in the field of glycomics in Berlin. The consortium, funded by the „Zukunftsfond Berlin“, consists of Glycotope GmbH, the biochemical & microbiological institute of the Charité represented by Professor Dr. Werner Reutter as well as the institute for clinical chemicals and pathobiochemics, represented by Professor Dr. Rudolf Tauber plus the Max-Dellbrück Center, represented by Dr. Wolfgang Kemmner. Further information: www.glykostrukturfabrik.de